Trial Profile

A Phase Ib/II Study to Evaluate the Efficacy, Safety and Tolerance of HLX43 (an Anti-PD-L1 Antibody Conjugated) Combined With HLX07 (a Recombinant Anti-EGFR Humanized Monoclonal Antibody) or Serplulimab in Patients With Advanced or Metastatic Colorectal Cancer

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 21 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

11 Feb 2026 Status changed from not yet recruiting to recruiting, according to a Henlius Biotech media release.
11 Feb 2026 According to a Henlius Biotech media release, the first patient has been dosed in China in a Phase 1b/2 trial(HLX43-mCRC202), for the company's innovative programmed death-ligand 1 (PD-L1) antibody-drug conjugate (ADC), HLX43, in combination with serplulimab, in patients with advanced or metastatic colorectal cancer.
02 Feb 2026 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com